Title: Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with
vedolizumab or ustekinumab: findings from SOJOURN
Version: 2 Date: 22 Nov 2022
Reviewer's report:
The paper addresses the risk of surgery in biologic-naïve CD patients treated with vedolizumab
and ustekinumab.. the number of patients enrolled is remarkable (1,222 included patients)
although described in a retrospective observational study. The main point is about choosing
a treatment for so many patients. The median age of the population is 47 years. the frailty of
the population is indicated only by a higher Charson Comorbidity Index, Patient characteristics
should be more detailed (such as the choice of the two drugs versus for example anti-TNF)
Title: Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with
vedolizumab or ustekinumab: findings from SOJOURN
Version: 2 Date: 22 Nov 2022
Reviewer's report:
The paper addresses the risk of surgery in biologic-naïve CD patients treated with vedolizumab
and ustekinumab.. the number of patients enrolled is remarkable (1,222 included patients)
although described in a retrospective observational study. The main point is about choosing
a treatment for so many patients. The median age of the population is 47 years. the frailty of
the population is indicated only by a higher Charson Comorbidity Index, Patient characteristics
should be more detailed (such as the choice of the two drugs versus for example anti-TNF)
Please review this paper.
user
Title: Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with
vedolizumab or ustekinumab: findings from SOJOURN
Version: 2 Date: 22 Nov 2022
Reviewer's report:
The paper addresses the risk of surgery in biologic-naïve CD patients treated with vedolizumab
and ustekinumab.. the number of patients enrolled is remarkable (1,222 included patients)
although described in a retrospective observational study. The main point is about choosing
a treatment for so many patients. The median age of the population is 47 years. the frailty of
the population is indicated only by a higher Charson Comorbidity Index, Patient characteristics
should be more detailed (such as the choice of the two drugs versus for example anti-TNF)
assistant